Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Paul Johns
Trade Marks

Samsung Bioepis releases second US Biosimilars Market Report

Jul 11, 2023

Samsung Bioepis has released its second US Biosimilar Market Report.  The quarterly report has updated price details of all products with launched biosimilars including updated 2023 Q3 average sale price (ASP) trends and wholesale acquisition cost (WAC) trends. For adalimumab: 

  • Organon/Samsung Bioepis’ Hadlima® and Coherus’ Yusimry® have a low WAC: ~85% less than Humira®  
  • Celltrion’s Yuflyma®, Boehringer Ingelheim’s Cyltezo®, and Fresenius Kabi’s Idacio® have a high WAC, only -5~7% below Humira®  
  • Amgen’s Amjevita®, Sandoz’s Hyrimoz®, and Biocon Biologics’ Hulio® are offering two pricing options including both a low and a high WAC    

Samsung Bioepis launched its first US Biosimilars Market Report on 18 April 2023, predicting that biosimilars will save US$181B in five years in the US.